TNFSF10 and osteosarcoma: Therefore, in our current study, we treated osteosarcoma cells with TRAIL and low-dose TMS (2.5, 5 μm) to evaluate whether TMS could sensitize these cells to TRAIL-mediated apoptotic cell death.